CAI

Caris Life Sciences Stock Analysis

AI Rating

Fair
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 2/10
Caris Life Sciences sales and earnings growth
CAI Growth
Fair
  • Revenue Y/Y↑ 84.50%
  • EPS Y/Y↑ 39.94%
  • FCF Y/Y↑ 158.23%
Caris Life Sciences gross and profit margin trends
CAI Profitability
Good
  • Gross margin ↑ 68.70%
  • EPS margin↓ -45.30%
  • ROIC 5Y↑ 0.00%
Caris Life Sciences net debt vs free cash flow
CAI Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 1.6

Caris Life Sciences stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Diagnostics & Research stocks